Abstract: The present invention provides compositions and methods for preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion using one or more estrogenic agents.

Abstract: The present invention relates to a method of treating cellular proliferative diseases, in particular cancer, which comprises administering a modulator of the activity of the mitotic kinesin KSP, wherein the activity of the KSP modulator is dependent on the presence of microtubules. It is believed that the KSP modulators utilized in the instant method bind to the KSP protein in a previously unreported manner, since the compounds do not bind competitively with respect to either microtubules or ATP, the substrates of KSP. The modulators useful in the instant methods are furthermore not active against the non-microtubule stimulated activity of KSP. Cellular proliferative diseases that may be treated using the method disclosed herein are, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation.

Abstract: The invention relates to novel aldolase-inhibiting compounds that can be advantageously used as medicaments (in therapeutic doses), especially for treating certain cancers, due to the inhibition efficacy thereof. An inventive compound corresponds to general formula (I) wherein the aldehyde group (—CHO) and the phenol group (—OH) are linked to two carbon atoms adjacent to the same aromatic chain, i.e., the first aromatic chain, and R is a phosphate group or a phosphate group mimetic linked to a carbon atom of the second aromatic chain.

Abstract: The invention relates to a pharmaceutical composition which is suitable in particular for use as purgative (cathartic), where the composition comprises in combination and in each case in pharmaceutically effective amounts (A) senna fruit dry extract and (B) plantago seeds (plantaginis ovatae semen). The composition can advantageously be manufactured by fluidized bed granulation. The composition is in particular free of guar gum, is dust-free, is dispersible in water and has a pleasant taste and can be supplemented straightforwardly with vitamins, minerals, trace elements and the like.

Abstract: Disclosed are anti-viral compositions containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients), and a pharmaceutical carrier. Also disclosed are methods of treating lesionous symptoms of a viral infection involving applying an effective amount of the anti-viral composition to the lesions.

Abstract: A phenolic fraction of fruit obtained from the Rosaceae family and also to the process for the specific extraction of this fraction. The phenolic fraction is rich in dihydrochalcones (phloridzin and phloretin) and may be used as a cosmetic, dietary, or nutraceutical preparation.

Abstract: Compounds of formula II wherein each R1 and R2 is independently selected from H and —P(O)(R3)(R4), provided that at least one of R1 and R2 is —P(O)(R3)(R4); each R3 and R4 is independently selected from the group consisting of H, —OH, C1-C6 alkyl and C1-C6 alkoxy; or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising a compound of formula II, and methods of administering such compounds and compositions.

Abstract: Modified green tea polyphenols and methods of their use are provided. One aspect provides compounds and compositions containing green tea polyphenols with one on more ester-linked fatty acids.

Abstract: Organic amine salts of compounds of the formula: and their pharmaceutically acceptable salts, and uses in medical therapy are provided.

Abstract: Orlistat is an oral lipase inhibitor that blocks the absorption of ingested fats from the small intestines, to enable proven weight loss. Fat-soluble vitamin deficiencies can be a consequence of orlistat use, especially if used for a long time without medical supervision. The present invention comprises a fat-soluble-only vitamin complex, specifically for use with orlistat, which vitamin complex contains a significantly increased amount of vitamin D, to prevent osteoporosis and to reduce fracture risk.

Abstract: Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a Croton spp. or a Calophyllum spp. In particular, the invention relates to a formulation of a proanthocyanidin polymer composition which protects the composition from the effects of stomach acid after oral administration, particularly to those formulations which are enteric coated. The invention also relates to methods of producing a directly compressible proanthocyanidin polymer composition, as well as compositions containing the directly compressible proanthocyanidin polymer composition.

Abstract: Compounds of formula I wherein at least one R1 is H and the remainder are CH2CO2K; R2 is and L is H are described. The compounds are useful as pharmaceutical compositions in the treatment of AIDS.

Abstract: Pharmaceutical compositions containing a proanthocyanidin polymer composition which are useful for the treatment and prevention of secretory diarrhea are provided. The invention specifically relates to pharmaceutical formulations of a proanthocyanidin polymer composition which has been isolated from a Croton spp. or a Calophyllum spp. In particular, the invention relates to a formulation of a proanthocyanidin polymer composition which protects the composition from the effects of stomach acid after oral administration, particularly to those formulations which are enteric coated. The invention also relates to methods of producing a directly compressible proanthocyanidin polymer composition, as well as compositions containing the directly compressible proanthocyanidin polymer composition.

Abstract: A composition which causes adult boring bark beetles to discontinue boring, discontinue laying eggs and become disoriented and bore out of the tree or cease boring altogether and die is described. Additional tests have shown that beetles will not infest a tree which has been treated with the composition. Furthermore, the composition also causes beetle larvae to cease boring and die and also causes egg sacks to shrivel and die.

Abstract: The present invention provides novel benzotropolone derivatives represented by the general formula: including neotheaflavate B and EGCGCa. The benzotropolone derivatives of the present invention are effective antioxidant and anti-inflammatory agents. The present invention also provides novel method of synthesizing benzotropolone compounds in high yields and method of treating inflammatory conditions using benzotropolone containing compounds.

Abstract: The use of a dihydrochalcone-rich polyphenolic fraction in the cosmetic treatment of mammals in order to limit the weight, to improve the aesthetic appearance of the body, and to treat certain non-pathological forms of obesity. The use of a dietary or nutraceutical composition based on this phenolic fraction. A composition based on this polyphenolic fraction for use as a medicinal product in the prevention of diabetes.

Abstract: The anti-angiogenic functions of a polysulfated, cyclic compound, ST104P, were investigated. ST104P exhibited excellent water solubility and low cytotoxicity to endothelial cells. ST104P potently inhibited the secretion of matrix metalloproteinase (MMPs) by endothelial cells. Moreover, ST104 also perturbed the migration and tube formation of endothelial cells. Application of ST104P abolished the neovascularization in chicken choroiallantoic membrane (CAM) in a dose-dependent manner. Besides, repeated administration of ST104P into Lewis lung carcinoma resulted in delayed tumor growth and prolonged the life span of tumor-bearing mice. These results indicated that ST104P inhibited angiogenesis and may hold promises for treatment of cancer and diseases or conditions caused by excessive angiogenesis.

Abstract: Non-toxic, naturally derived and economical compositions for treating and preventing bacterial or fungal disease in plants, especially citrus canker, wherein such compositions include various combinations of d-limonene, wax and monohydric alcohol are provided. Methods for making and using such compositions are also provided.

Abstract: The invention relates to the use of substituted bicyclo[3.3.1]nonan-2,4,9-triones, especially clusianon and clusianon derivatives, as pharmaceutical active ingredients or medicamentous active ingredients, especially for producing medicaments for the prophylactic and/or therapeutic (curative) treatment of tumour or cancer diseases, and of viral diseases. The above-mentioned compounds can be used in cytostatic agents and antiviral agents (virostatic agents). They are especially used as inhibitors of topoisomerases and telomerases and as regulators during the MAP kinase signal transduction and can thus intervene on a cellular scale in the mechanism for multiplication of tumour or cancer cells and viruses.

Abstract: The invention described herein encompasses methods and compositions of preventing or treating cancer comprising the administration of a combination of therapeutically effective amount of catechins, a group of polyphenols found in green tea, and Capsicum extracts. Compositions of catechins include but not limited to, epigallocatechin gallate (EGCg), epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC). The unique compositions of the invention contain various combinations of the catechins and Capsicum extracts, in combination with each other or other therapeutic agents and are used to treat primary and metastatic cancers in humans. The invention also encompasses the varying modes of administration of the therapeutic compounds, including a formulation which may be used as a therapeutic compound for the treatment of cancer or as a dietary supplement for the prevention of cancer.

Abstract: The invention relates to a clusianon isomer and to the use thereof, in particular as a pharmaceutical or medical active ingredient, in particular for producing medicaments for the prophylactic and/or therapeutic (curative) treatment of tumor or cancer diseases as well as viral diseases. The aforementioned compound can be used in cytostatics and antiviral agents (virostatics). Said compound acts, in particular, as a topoisomerase and telomerase inhibitor and as a regulator in the MAP kinase signal transduction. Said compound can thus intervene at the cellular level in the proliferation mechanism of tumor or cancer cells and viruses.

Abstract: The invention relates to the use of compounds of formula (I): wherein X is —C(O)—, —C(S)—, —C?NOH, or —CH(R7)— wherein R7 is hydrogen, hydroxy, C1-7alkoxy, —OR8 or —NR8R9 (wherein R8 is a group —Y1R10 (wherein Y1 is a direct bond, —C(O)—, —C(S)—, —S—, —C(O)O, —C(O)NR11—, —SO2— or —SO2NR12— (wherein R11 and R12, which may be the same or different, each independently represents hydrogen, C1-3alkyl or C1-3alkoxyC2-3alkyl) and R10 is as defined herein, and R9 includes hydrogen; R1, R2 and R3 are as defined herein and are preferably methyl; R4, R5 and R6 are as defined herein with the proviso that R5 is not hydroxy, alkoxy, substituted alkoxy, —OPO3H2, —O—C1-7alkanoyl or benzyloxy; and salts thereof in the manufacture of a medicament for use in the production of a vascular damaging effect in warm-blooded animals such as humans.

Abstract: The use of the reduction products of hyperforin and adhyperforin, pharmaceutically acceptable salts or esters thereof, in the pharmaceutical and/or nutritional field, in particular in the treatment of depression and Alzheimer's disease.

Abstract: The present invention provides novel benzotropolone derivatives represented by the general formula: including neotheaflavate B and EGCGCa. The benzotropolone derivatives of the present invention are effective antioxidant and anti-inflammatory agents. The present invention also provides novel method of synthesizing benzotropolone compounds in high yields and method of treating inflammatory conditions using benzotropolone containing compounds.

Abstract: Hyperforin and adhyperforin halogenated derivatives of general formula (I) in which X, R and R1 have the meanings as defined in the disclosure, the process for the preparation thereof and the use thereof in the pharmaceutical and/or nutritional field, in particular in the treatment of depression, and Alzheimer's disease.

Abstract: A phenolic fraction of fruit obtained from the Rosaceae family and also to the process for the specific extraction of this fraction. The phenolic fraction is rich in dihydrochalcones (phloridzin and phloretin) and may be used as a cosmetic, dietary, or nutraceutical preparation.

Abstract: A process of isolation of pure Acteoside of high hepatoprotection from plant Colerbrookea oppositifolia, said process comprising steps of drying aerial parts of the plant, grounding the dried parts into powder, percolating the powder with water or ethanol for 3-4 times to obtain an extract, filtering the extract for clearing of suspended particles to obtain supernatant, drying the supernatant at about 45 to 55° C.

Abstract: The formulation includes a combination of a chalcone, specifically, methylhydroxychalcone polymer, in the amount of 6 mg to 24 mg, and chromium, in the amount of 500 mcg to 2000 mcg. The formulation also includes a plurality of vitamins and nutrients, vitamins B6, C, E and K including green tea polyphenols and other nutrients.

Abstract: A method for isolating the bioactive component of the water-soluble extract of Uncaria tomentosa known as C-MED-100®, comprising (i) precipitating the spray drying carrier from C-MED-100®; (ii) using the resulting C-MED-100® to obtain a spotting mixture for thin layer chromatography (TLC); (iii) spotting the C-MED-100® spotting mixture on pre-run TLC plates and eluting the plates to obtain the fluorescing band with Rf=0.2-0.3; (iv) scraping off the Rf=0.2-0.3 band, eluting it in ammonia and freeze drying the eluted band to form a powder; and (v) extracting the powder with methanol to remove solubilized silica gel, concentrating the methanol solution and crystalizing the concentrated solution to obtain the bioactive component. The isolated bioactive component is a quinic acid analog, preferably quinic acid lactone. A pharmaceutical composition comprising a pharmaceutically effective amount of the bioactive component and a nontoxic inert carrier or diluent.

Abstract: The present invention relates to a method for reducing inflammation in the skin and/or treating inflammatory skin disorders, pain, or pruritis by topically applying a composition comprising totarol or a pharmaceutically-acceptable ester thereof.

Abstract: A pharmaceutical composition for prevention and treatment of cancer, cardiovascular disease and antioxidation contains resveratol. The new method of process for producing resveratol is extracted resveratol from oil residue and stems of peanuts or stems of other cheap herbs. Derivates of resveratol include procyanidins, polydatin, peceid, anthraglycoside, emodin, chrysophanol and quercetin.

Abstract: Disclosed are anti-viral compositions containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients), and a pharmaceutical carrier. Also disclosed are methods of treating lesionous symptoms of a viral infection involving applying an effective amount of the anti-viral composition to the lesions.

Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

Abstract: An antimicrobial compound, composition containing such compound, and method of use of the same for reducing the presence of microorganism on a substrate or in a fluid environment comprising an antimicrobial effective carrier and one or more essential antimicrobial compounds including non-halogenated naphthol compounds.

Abstract: This invention relates to a method for extracting, fractionating and purifying polyphenolic compounds originating from plants, wherein the purification is performed by adsorption on an adsorbing styrene-divinyl benzene resin, followed by the elution of the polyphenolic compounds.

Abstract: Disclosed are novel materials separated from Ecklonia cava, a method for extracting and purifying the same, and the use thereof for antioxidants. The method comprises extracting antioxidative ingredients from powdered Ecklonia cava one or more times with an organic solvent; fractionating the antioxidative ingredients one or more times in solvents; and purifying the solvent fractions by chromatography. Superior in scavenging activity and thermal stability, the extract from Ecklonia cava can be used as antioxidants and is suitable in commercialization.

Abstract: The invention relates to compounds of the formula (I) 1

Abstract: Triphenylmethane derivatives of the formula (I) are disclosed.

Abstract: The invention described herein encompasses methods and compositions of preventing or treating cancer comprising the administration of a combination of catechins and vanilloids. Compositions of catechins include but not limited to, epigallocatechin gallate (EGCg), epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC). In a preferred embodiment the catechins have been treated with tannase. Compositions of vanilloids include, but are not limited to vanillylamine, the head group of capsaicin. The unique compositions of the invention contain various combinations of the catechins and vanilloids, in combination with each other or other therapeutic agents and are used to treat primary and metastatic cancers in humans. The invention also encompasses various modes of administration of the therapeutic compounds, including formulations which may be used as a dietary or nutritional supplement or as a therapeutic compound.

Abstract: A method of forming a water soluble biocidal film on a solid household, food preparation, or medical surface, which protects the solid surface against reinfection by microorganisms, includes providing a liquid biocidal composition comprised of, based on total weight of the liquid biocidal composition from 0.1 to 5.0 wt. % of a phenolic biocide; from an amount effective to impart film-forming properties to the liquid biocidal composition up to 8 wt. % of a polyvinyl pyrrolidone polymer or copolymer; and an aqueous alcoholic solvent in which the phenolic biocide and the polyvinylpyrrolidone polymer or copolymer are dissolved; treating the solid surface with the liquid biocidal composition; and evaporating the aqueous alcoholic solvent to provide a clear film, wherein a ratio of the phenolic biocide to the polyvinylpyrrolidone polymer or copolymer is selected to range from 1:0.8 to 1:3 so that a complex there between is provided which dries clear.

Abstract: Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Abstract: Pharmaceutical compositions and methods for treating androgen related disorders. The pharmaceutical compositions may include a 5&agr;-reductase inhibitor, such as natural and synthetic flavanoids, catechols, curcumin-related substances, quinones, catechins, particularly epigallocatechin derivatives, fatty acids, and the salts, esters, analogues, pro-drugs, isomers, racemic mixtures, or derivatives of any of the foregoing. The use of testosterone (or DHT) combinations with the aforementioned 5&agr;-reductase inhibitor compounds is also contemplated.

Abstract: The invention provides non-steroidal estrogenic compounds with estrogenic and anti-estrogenic compounds effects for treatment of estrogen-deficiency related disorders, which compounds are having formula (I) wherein, one of Ra or Rb is 'Re; Re and 'Re are OH, optionally independently etherified or esterified; X is N or —C(R1)—, wherein R1 is H1 halogen, CN, optionally substituted aryl, (1C-4C)alkyl, (2C-4C)alkenyl, (2C-4C)alkynyl or (3C-6C)cycloalkyl, which alkyl, alkenyl, alkynyl and cycloalkyl groups can optionally be substituted with one or more halogens; Y is N or —C(R2)—, with the proviso that X and Y are not both N, wherein R2 has the same meaning as defined for R1; Z is C(R3,'R3)— or —C(R4,∝R4)—C(R5,'R5)—, wherein R3, 'R3, R4, 'R4, R5, and 'R5, independently arc H, (1C-4C)alkyl, (2C-4C)alkenyl or (3C-6C) cycloalkyl, which alkyl, alkenyl and cycloalkyl groups can optionally be substituted with one or more halogens.

Abstract: The present invention relates to the use of substrates of an UDP-glucuronosyltransferase (UGT) and salts thereof, for the prevention and/or the treatment of neurological disorders. In preferred embodiment, the present invention relates to the use of substrates of at least an UDP-glucuronosyltransferase (UGT) expressed in brain and salts thereof, for the prevention and/or the treatment of neurological disorders. It further relates to the use of said substrates, and salts thereof, for preventing and/or treating glutamate cytotoxicity, and more specifically of glutamate induced neurological disorders. Additionally, it concerns the use of said substrates, and salts thereof, for making drugs exerting an inhibitory effect on the release of glutamate.

Abstract: Incubations with Nocardia sp., NRRL 5646 were conducted to produce new derivatives of the abietane-diterpene chemoprotectant and antioxidant, carnosic acid. Reduction of the C-20 carboxylic acid functional group followed by methylation at the C-12 phenol afforded the novel compound 11,20-dihydroxy-12-methoxy-abiet-8,11,13-triene. Oxidative cyclization of carnosic acid to carnosol followed by dihydroxylation at the isopropyl moiety afforded the novel compound 11,12,16,17-tetrahydroxy-7-10-(epoxymethano)-abiet-8,11,13-triene-20-one. The metabolites are new carnosic acid derivatives whose structures were confirmed by mass spectrometry and NMR spectroscopic analysis. The radical quenching properties of the new metabolites using the 2,2-diphenyl-1-picrylhydrazyl (DPPH) free-radical scavenging assay showed activities improved over that of mixed tocopherols and carnosic acid.

Abstract: An antimicrobial compound, composition containing such compound, and method of use of the same for reducing the presence of microorganism on a substrate or in a fluid environment comprising an antimicrobial effective carrier and one or more essential antimicrobial compounds including non-halogenated naphthol compounds.

Abstract: A method for indirectly stimulating a vagus nerve of a patient includes the steps of positioning one or more electrodes in the vicinity of the vagus nerve and then actuating the electrode(s) to create an electrical field for stimulating the vagus nerve. Disclosed embodiments include positioning one or more electrodes in the esophagus, trachea, or jugular vein, on the neck of the patient, and combinations thereof.

Abstract: The invention relates to compounds of the formula: in which R is a saturated or unsaturated, straight or branched, C1-C22 acyl group, optionally having one or more substituents, which can be the same or different, selected from halogen atoms, nitro, amino, C1-C6-alkylamino, di-C1-C6-alkylamino, C1-C6-acylamino groups; a cycloaliphatic or aromatic acyl residue in which the aromatic moiety optionally has one or more substituents, which can be the same or different, selected from halogen atoms, hydroxy, methoxy, amino groups; a glycidic residue in which one or more hydroxy groups are optionally alkylated or acylated. The invention further relates to methods for extracting and extracts of these compounds from Hypericum perforatum as well as their use as active ingredients in antidepression medication.

Abstract: The present invention relates to novel compositions based on hydrated lipidic lamellar phases or liposomal compositions, prepared by combining different lipid molecules, synthetic and/or from natural sources, said compositions comprising at least one of a) labd-13-ene-8&agr;, 15-diol and/or derivatives thereof; b) labd-14-ene-8, 13-diol or derivatives thereof; c) 3&bgr;-hydroxy-labd-14-ene-8, 13-epoxy and/or derivatives thereof, d) a plant extract containing the aforementioned labdenes or derivatives thereof. The compositions of the invention exhibit cytotoxicity against cancerous cells and are utilized for the treatment of tumors and leukemias.

Abstract: The present invention relates to novel compositions based on hydrated lipidic lamellar phases or liposomal compositions, prepared by combining different lipid molecules, synthetic and/or from natural sources, said compositions comprising at least one of a) labd-13-ene-8?, 15-diol and/or derivatives thereof; b) labd-14-ene-8, 13-diol or derivatives thereof; c) 3?-hydroxy-labd-14-ene-8, 13-epoxy and/or derivatives thereof, d) a plant extract containing the aforementioned labdanes or derivatives thereof. The compositions of the invention exhibit cytotoxicity against cancerous cells and are utilized for the treatment of tumors and leukemias.